Bristol-Myers Squibb Cuts Deal, Delaying Threat to Top-Selling Revlimid

Bristol-Myers Squibb Cuts Deal, Delaying Threat to Top-Selling Revlimid

Submitted by admin on September 17, 2020 - 11:09pm
Source: 
Motley Fool
News Tags: 
Bristol-Myers Squibb
Dr Reddy's
Revlimid
Multiple Myeloma
Headline: 
Bristol-Myers Squibb Cuts Deal, Delaying Threat to Top-Selling Revlimid
snippet: 

Bristol-Myers Squibb (NYSE:BMY) is granting Dr. Reddy's Laboratories (NYSE:RDY) a volume-limited license to produce a generic version of its blockbuster multiple myeloma drug, Revlimid, beginning in 2022.

Do Not Allow Advertisers to Use My Personal information